#ASCO21: A week after nabbing priority review, Kite unveils the pivotal data it hopes will lead to a new CAR-T approval
Just less than a year ago, Gilead’s Kite won a landmark okay for its second CAR-T therapy, with data that former head of global development Ken Takeshita hailed as “better than Yescarta.” Now, ahead of #ASCO21, Kite is unveiling pivotal data to back the drug in a new type of cancer.
Of 55 patients who received Tecartus for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), 71% saw their signs of cancer disappear, new head of clinical development Frank Neumann said. However, some still had incomplete hematologic recovery (which the company defined as complete response with incomplete hematologic recovery, or CRi).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.